WOODLAND HILLS, Calif.--(BUSINESS WIRE)--OSI Consulting, Inc., a global provider of business and technology solutions, announced today that it has changed its company name to OSI Digital, Inc. This ...
A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. Background: OSI-906 is a potent inhibitor of IGF-1R and IR tyrosine kinase ...
MELVILLE, N.Y.--(BUSINESS WIRE)--June 30, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP), announced today that its diabetes and obesity business unit (OSI) Prosidion, has granted Merck & Co. Inc. a ...
MELVILLE, N.Y., Mar 16, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. ("OSI") today commented on Astellas Pharma Inc.'s ("Astellas") announcement that it has submitted a slate of 10 director ...
Notorious short seller and Muddy Waters Research Founder Carson Block has a new target: technology and medical supply company OSI Systems, Inc. OSIS. In a new short film posted on the company’s ...
OSI recently moved one of its clinics to Providence St. Joseph’s Helen Caloggero Women’s and Family Center in Orange Orthopaedic Specialty Institute (OSI) is merging with three other practice groups, ...
OSI Systems, Inc. (NASDAQ: OSIS) (the “Company” or “OSI”) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior ...
HAWTHORNE, Calif.--(BUSINESS WIRE)-- OSI Systems, Inc. (OSIS) (the “Company” or “OSI”) today announced the pricing of its offering of $500 million aggregate principal amount of 0.50% convertible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback